改造病毒样粒子的定向进化,提高了生产和转导效率
Aditya Raguram1,2,3,4, Meirui An5,6,7, Paul Z Chen5,6,7,8
1Merkin Institute of Transformative Technologies in Healthcare, Broad Institute of MIT and Harvard, Cambridge, MA, USA. araguram@wi.mit.edu.
Nature biotechnology
|November 13, 2024
概括
工程病毒样粒子 (eVLP) 通过使用一种新的条形码系统来改进它们的传递能力. 由此产生的第五代eVLP显示了将遗传物质传递到人体细胞中的增强效能.
科学领域:
- 生物技术是生物技术.
- 分子生物学分子生物学
- 病毒学 病毒学
背景情况:
- 工程病毒样颗粒 (eVLP) 是一种先进的平台,可以暂时输送蛋白质和RNA等治疗分子.
- 目前的eVLP技术需要优化,以提高生产效率和细胞传导效率.
研究的目的:
- 开发一个实验室进化系统,以发现具有优越性质的eVLP变体.
- 在人类细胞中设计具有提高生产和基因传递效率的eVLP体.
主要方法:
- 在无DNA的eVLP货物中使用带条码指导RNA的系统被用于图书馆标签.
- 应用了定向进化策略,以选择具有增强生产和转导的eVLP变体.
- 有益的头突变被结合起来,创造了先进一代的eVLP.
主要成果:
- 开发了第五代 (v5) eVLP,与v4 eVLP相比,其向哺乳动物细胞的传递效率增加了2-4倍.
- 在v5 eVLPs中的突变优化了核蛋白货物的包装和交付.
- 在进化变体中观察到eVLP体结构的显著变化.
结论:
- 带有条形码的eVLP进化系统有效地识别了具有改进性质的变体.
- 开发的v5 eVLP代表了短暂基因传递载体的重大进步.
- 这种方法对未来开发基于eVLP的增强疗法充满希望.
相关概念视频
Bioreactor Controls-III
Strain improvement is a foundational strategy in industrial microbiology aimed at maximizing microbial productivity, particularly because natural isolates typically yield commercially valuable products in very low concentrations. Although optimizing the culture medium and environmental conditions can improve yields, these adjustments are inherently limited by the organism’s genetic potential. As a result, the focus shifts toward genetic modifications to enhance biosynthetic capacity. The...
Production of Pharmaceuticals
Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Vaccine Production
Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...


